CLINICAL_TRIALS
trial_result
· 2025-05-28
Clinical Trial Update: A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas [Phase 1]
Summary
A Phase 1 safety study of RTA 744 in patients with recurrent high-grade gliomas has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Glioma | Phase 1 | Status: COMPLETED